Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Prostatic Neoplasms 1Philadelphia Chromosome 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Hematologic Neoplasms 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

ibrutinib 1Povidone-Iodine 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Bronchiolitis Obliterans Syndrome × Dasatinib × Clear all
NCT00349518 2016-02-17

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Bristol-Myers Squibb

Phase 2/3 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡